Alprazolam

Generic Name: Alprazolam

Brand Names: Niravam, Xanax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₃ClN_₄

CAS Number: 28981-97-7

Unique Ingredient Identifier: YU55MQ3IZY

Background: Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.

Indication: Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.

Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.

Associated Conditions: Generalized Anxiety Disorder, Panic Disorder

Clinical Trials

Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety.

Phase 2

Conditions: Generalized Anxiety Disorder

Interventions: Drug: alprazolam 1mg
Dietary Supplement: Galphimia glauca standardized extract

First Posted Date: 2018-10-11

Last Posted Date: 2020-07-14

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 122

Registration Number: NCT03702803

Locations: 🇲🇽
Regional General Hospital Number 1 at Cuernavaca, Morelos. Mexican Insitute of Social Security, Cuernavaca, Morelos, Mexico

Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Gamma-Aminobutyric Acid (GABA)
Drug: Alprazolam

First Posted Date: 2018-08-17

Last Posted Date: 2022-11-02

Lead Sponsor: Per-Ola Carlsson

Target Recruit Count: 35

Registration Number: NCT03635437

Locations: 🇸🇪
Uppsala University Hospital, Uppsala, Sweden

Sedative Premedication in Coronary Angiography

Not Applicable

Conditions: Sedative Premedication
Coronary Angiography

Interventions: Drug: Alprazolam 0.5 mg
Drug: Placebo Oral Tablet

First Posted Date: 2018-07-03

Last Posted Date: 2018-10-12

Lead Sponsor: Universitair Ziekenhuis Brussel

Target Recruit Count: 264

Registration Number: NCT03576456

Locations: 🇧🇪
Adriaan Wilgenhof, Brussels, Jette, Belgium

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Alprazolam Placebo
Drug: Alprazolam
Drug: Cenobamate placebo
Drug: Cenobamate

First Posted Date: 2018-04-26

Last Posted Date: 2024-11-07

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 53

Registration Number: NCT03509285

Locations: 🇺🇸
Vince & Associates Clinical Research, Inc, Overland Park, Kansas, United States
🇨🇦
INC Research, Inc., Toronto, Ontario, Canada

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Staccato Alprazolam
Drug: Placebos

First Posted Date: 2018-03-27

Last Posted Date: 2021-02-03

Lead Sponsor: Engage Therapeutics, Inc.

Target Recruit Count: 156

Registration Number: NCT03478982

Locations: 🇦🇺
The Alfred, Melbourne, Victoria, Australia
🇺🇸
Lewis Katz School of Medicine at Template University, Philadelphia, Pennsylvania, United States
🇺🇸
Hoag Hospital, Newport Beach, California, United States

and more 64 locations